U.S. recession will inevitably make many biopharma companies change course. However, it could cause some biotechs to change for the better.

The U.S. Department of Justice indicted former CytoDyn Inc. CEO Nader Z. Pourhassan and the CEO of Amarex Clinical Research on multiple counts of fraud.

Pfizer is rapidly scaling up its AI/ML efforts in a collaborative effort intended to get transformative medicines to patients faster.

Researchers at the University of Tokyo have used artificial DNA to target and kill cancer cells in a completely new way. The method was effective in lab tests against human cervical cancer- and breast cancer-derived cells, and against malignant melanoma cells from mice. The team created a pair of chemically synthesized, hairpin-shaped, cancer-killing DNA.

Jazz Pharmaceuticals exercised its option on Zymeworks' promising anti-cancer agent.

The FDA placed a clinical hold on Entrada's experimental DMD candidate.

Asklepios BioPharmaceutical, Inc. (AskBio), a wholly-owned and independently-operated subsidiary of Bayer AG, today announced that the FDA's approval of a new adeno-associated virus (AAV) gene therapy to treat adults with hemophilia B marks another milestone for the advancement of AAV therapeutics and highlights the important research contributions made by AskBio Co-Founder, President and Chief Scientific Officer, R. Jude Samulski, PhD.

Madrigal's NASH drug hits the mark in late-stage trial.

In one of the first large, real-world studies comparing the effectiveness of COVID-19 vaccines versus natural immunity in protecting against death, hospitalizations and emergency department (ED) visits for any cause, including COVID, research-scientists from Regenstrief Institute, Indiana University School of Medicine and Vanderbilt University Medical Center report that people of all age groups benefited significantly more from vaccination than natural immunity acquired from a previous COVID infection.

Sanofi and Innate Pharma expand their longtime collaboration by licensing up to three NK cells engager programs in cancer immunotherapy valued at more than $1.4 billion.

Psychedelic and psychedelic-assisted therapies in the neuropsychiatric space have stalled for decades.

Q1 is the time when life science professionals are ramping up their job search efforts. If this applies to you, here are some tips to help you get a head start and prepare for your Q1 job search.

Lilly digs deeper into metabolic diseases via GPCR partnership with Sosei.

Today, the U.S. Food and Drug Administration approved Adstiladrin (nadofaragene firadenovec-vncg), a non-replicating (cannot multiply in human cells) adenoviral vector based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.

Scientists at UC San Francisco (UCSF) have engineered T cells to produce a potent anti-cancer cytokine, but only when they encounter tumor cells. The immunotherapy eliminated melanoma and pancreatic cancer in mice without major side effects, and it offers a promising new strategy for fighting these and other hard-to-treat cancers.

Successfully managing Gen Z employees in the workplace requires knowing about their distinctive traits and the factors that set them apart.

Astellas’ zolbetuximab hit the mark in a second late-stage trial in Claudin-18.2-positive gastric cancer.

Ocugen gets the go-ahead from the FDA to trial its late-stage regenerative cell therapy.

Covalent biologic company Enlaza launches with $61M in seed financing.

Roche (SIX: RO, ROG; OTCQX: RHHBY) has entered into a U.S. focused collaboration with Pfizer to drive awareness and educate on the importance of timely COVID-19 testing, available treatment options, symptoms and the high-risk factors that can increase the chance of progressing to severe illness.